Patent notice of allowance granted for China
Futura Medical PLC has received notice of patent allowance for its Eroxon product in China, securing protection until 2040 and enhancing its competitive position in a market with an estimated 50% prevalence of erectile dysfunction among 700 million adult males. This allowance adds to existing protection in Europe, Hong Kong, Taiwan, and the US, with further applications pending and a divisional patent planned for early 2026. The company is actively seeking partners in China to leverage this significant commercial opportunity.
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that it has been granted notice of allowance of its patent which will provide protection for Eroxon® until 2040 in China.
The prevalence of erectile dysfunction in the 700 million adult males in China is estimated to be approximately 50%, which represents a considerable commercial opportunity.
This allowance adds to the Company's existing protection in Europe, Hong Kong, Taiwan and the US, further consolidating its global IP. Other applications in additional markets remain pending. In addition, Futura Medical is planning to extend its IP protection in China by filing a divisional patent in early 2026.
Alex Duggan, CEO of Futura, commented: "The grant of this patent in China will mark an important milestone for Futura in one of the largest Erectile Dysfunction markets globally. We now have an enhanced competitive position which supports our commercial strategy as we actively seek partners in this market. We look forward to updating the market on progress in due course."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.